Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
194.79
+2.89 (+1.51%)
Official Closing Price
Updated: 4:10 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
4,752,261
Open
192.60
Bid (Size)
194.60 (5)
Ask (Size)
195.33 (5)
Prev. Close
191.90
Today's Range
190.27 - 196.13
52wk Range
135.85 - 199.95
Shares Outstanding
N/A
Dividend Yield
3.04%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Today 15:06 EDT
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for...
Via
Benzinga
Exposures
Product Safety
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
September 26, 2024
Via
Benzinga
Performance
YTD
+21.88%
+21.88%
1 Month
-0.58%
-0.58%
3 Month
+15.27%
+15.27%
6 Month
+6.97%
+6.97%
1 Year
+27.21%
+27.21%
More News
Read More
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
September 26, 2024
Via
Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
September 26, 2024
Via
The Motley Fool
Behind the Scenes of AbbVie's Latest Options Trends
September 24, 2024
Via
Benzinga
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
September 20, 2024
Via
Benzinga
Exposures
Product Safety
Spotlight on AbbVie: Analyzing the Surge in Options Activity
September 20, 2024
Via
Benzinga
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
September 19, 2024
Via
Benzinga
Is ABBVIE INC Ready to Break Out of Its Range?
September 17, 2024
Via
Chartmill
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
September 19, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Abbie Inc Stocks Elliott Wave Technical Analysis - Wednesday, September 18,
September 18, 2024
Via
Talk Markets
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
September 17, 2024
Via
Benzinga
Topics
ETFs
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
September 16, 2024
Via
The Motley Fool
What the Options Market Tells Us About AbbVie
September 11, 2024
Via
Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity
September 09, 2024
Via
Benzinga
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
September 14, 2024
Via
The Motley Fool
3 Stocks to Buy and Hold Forever
September 14, 2024
Via
The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
September 14, 2024
Via
The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
Is This Company Still a Strong Buy After Tripling the S&P 500's Returns?
September 13, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
September 11, 2024
Via
Benzinga
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
September 10, 2024
Via
Benzinga
3 Things You Need to Know if You Buy AbbVie Stock Today
September 09, 2024
Via
The Motley Fool
3 No-Brainer Dividend Stocks to Buy in September
September 08, 2024
Via
The Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.